Two-thirds of patients with moderate or severe plaque psoriasis had complete or nearly complete clearance at 4 months with an ...

The TYK2 inhibitor deucravacitinib (Sotyktu) showed clinical potential in two diseases other than psoriasis, according to ...

A study finds that 99% of dietary advice for psoriasis on Instagram is low-quality, often unsubstantiated and posted by ...

Johnson & Johnson’s once-daily oral peptide has bested Bristol Myers Squibb’s reigning oral psoriasis med Sotyktu in a ...

A diet of fruits and vegetables, whole grains, low-fat dairy foods and lean meats, low in salt and sugar, is associated with ...

What if suffering isn’t just what’s happening, but our reactions to it? Discover why we keep doing what doesn't serve us and ...

Adults and adolescents treated with icotrokinra experienced improvements in their moderate to severe plaque psoriasis, ...

In a cohort of more than 11,000 patients from the U.K. and Ireland, a comparable proportion of new adalimumab users achieved ...

Positive results were reported for Johnson & Johnson's psoriasis drug during.a late-breaking research session today at the ...

ORLANDO -- More than 80% of patients with moderate or severe atopic dermatitis (AD) had at least 75% improvement after 12 ...

Results from multiple Phase III trials of Icotrokinra in moderate-to-severe plaque psoriasis and a Phase IIb trial in ...

Two posters presented at the 2025 American Academy of Dermatology Annual Meeting highlighted the importance of improving ...